Form 8-K · Current report
Thermo Fisher Scientific 8-K, filed Jul 23, 2026
- Filed
- CIK
- 0000097745
- Accession no.
- 0000097745-26-000138
Summary
Thermo Fisher Scientific reported second-quarter 2026 revenue of $11.99 billion, up 10% including 5% organic growth, with GAAP diluted EPS of $4.68 and adjusted EPS of $6.03; CEO Marc Casper said end markets continued to strengthen. The company announced the divestiture of its microbiology business, repurchased $1.0 billion of stock, launched new mass spectrometry and PCR products, and said it would provide updated 2026 guidance during its earnings call.
Key points
- Second-quarter 2026 revenue was $11.99 billion, up 10% from $10.85 billion a year earlier, with 5% organic growth.
- GAAP diluted EPS was $4.68, up 9%, and adjusted EPS was $6.03, up 13%; GAAP operating income was $2.09 billion and adjusted operating income was $2.73 billion.
- Thermo Fisher announced the divestiture of its microbiology business and repurchased $1.0 billion of stock during the quarter.
- It launched the Thermo Scientific Orbitrap Tribrid Apex and Orbitrap Excedion mass spectrometers and the Applied Biosystems PowerFlex Thermal Cycler, and announced a collaboration with Precision Health Research, Singapore for the PRECISE-SG100K population health study.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
Items reported
- 2.02Results of Operations and Financial Condition
- 9.01Financial Statements and Exhibits
From the filing
Item 2.02 Results of Operations and Financial Condition. On July 23, 2026, the Registrant announced its financial results for the fiscal quarter ended June 27, 2026. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Form 8-K and incorporated herein by reference. The information contained in this report and exhibits hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly…
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.